Search

everythinglearnresearchcommunity

for

Search:↓

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

QLT0267 stops hair follicle cell growth and movement.

CTP-543 is generally safe for treating alopecia areata.

JAK inhibitors like tofacitinib may effectively treat alopecia in children without major side effects.

Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.

JAK inhibitors show promise for treating various skin diseases.

Oral Janus kinase inhibitors are effective for treating alopecia areata in adults.

JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.

JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.

Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.

JAK inhibitors help hair growth by boosting beta-catenin activity in hair root cells.

Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.

Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.

JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.

Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.

A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.

Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.

The drug showed promise in treating renal cell carcinoma with manageable side effects.

Janus Kinase Inhibitors are promising new treatments for various skin conditions due to their effectiveness and safety.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.

Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.

PI3Kδ inhibition may effectively treat cutaneous chronic graft-versus-host disease.

Tofacitinib helped regrow hair in patients with alopecia, with few side effects.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

CI-1033 causes skin lesions in rats, similar to humans, due to EGF receptor inhibition.